Navigation Links
Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Date:12/10/2008

SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced the commencement of patient dosing for a Phase 1 clinical trial for a bisphosphonate administered with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20) as a subcutaneous (SC) injection. This study will explore the safety, tolerability and pharmacokinetics of SC administration of a bisphosphonate plus rHuPH20. Currently, injectable bisphosphonates must be administered intravenously (IV).

"We are pleased that the first clinical trial is underway for our bisphosphonate program, our third proprietary product development initiative to enter clinical studies," stated Jonathan Lim, M.D., President and CEO of Halozyme Therapeutics. "The bisphosphonate program joins insulin, for diabetes, and Chemophase, for superficial bladder cancer, our other two proprietary programs in clinical development. The goal of Halozyme's bisphosphonate program is to provide an alternative dosage formulation that may offer greater convenience, compliance and tolerability to patients for the treatment of osteoporosis."

This Phase 1 dose ranging clinical trial will assess the safety, tolerability and pharmacokinetics of a bisphosphonate with and without co-administration of rHuPH20 across a range of bisphosphonate concentrations and volumes and various rHuPH20 doses. The study will also compare SC administration of a bisphosphonate plus rHuPH20 to IV bisphosphonate alone.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase, for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit www.halozyme.com.

SafeHarbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the potential benefits of administering rHuPH20 with a bisphosphonate) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

    Halozyme Contact                           Media Contacts
    Robert H. Uhl                              Karen Sparks / Joleen Schultz
    Senior Director, Investor Relations        Mentus
    (858) 704-8264                             (858) 455-5500, x275/x215
    ruhl@halozyme.com                          karen@mentus.com
                                               jschultz@mentus.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
2. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
3. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
4. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
5. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
6. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
7. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
8. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
9. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
10. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... , the world , s ... and AV fistula intervention   OrbusNeich, a ... solutions, has expanded its portfolio to include products to ... balloons are the company,s first entry devices for lower ...
(Date:5/24/2016)... 2016 Les ... la première endoprothèse à double thérapie au ... portant sur les membres inférieurs et la ... entreprise mondiale spécialisée dans la fourniture de ... a élargi son portefeuille pour inclure des ...
(Date:5/24/2016)... May 24, 2016 Dutch surgeons have launched ... around the world and treat patients on a global scale. Medical ... , Asia and the US have already ... messaging and networking in a totally secure environment. Education  ... war zone working together with a surgeon at Harvard to treat ...
Breaking Medicine Technology:
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Sterling Global ... feature a unique and patented refillable hanging wipe dispenser. The campaign kick-off video is ... and will end June 25, 2016. The goal is to raise $1,000 per day ...
(Date:5/24/2016)... ... , ... To better understand the impact of lung cancer in women, the ... lung cancer. Today, the Lung Association announced Sharad Goyal, MD , as the recipient ... the American Lung Association’s LUNG FORCE initiative, which raises awareness of the impact of ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... corporate identity and website at its “Transforming Outcomes” User Conference in Las Vegas ... reflect i2i’s ongoing success to set the market standard for meaningful population health ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... of communication enabled solutions and managed services today announced a strategic partnership ... enterprise contact center market. , Altura, one of Avaya’s largest Platinum Business ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... How to ... · Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the ... that human error will ever be totally eliminated, many human performance problems can be ...
Breaking Medicine News(10 mins):